Follow-Up Visit Patterns in an Antiretroviral Therapy (ART) programme in Zomba, Malawi
Identifying follow-up (FU) visit patterns, and exploring which factors influence them are likely to be useful in determining which patients on antiretroviral therapy (ART) may become Lost to Follow-Up (LTFU). Using an operation and implementation research approach, we sought 1) to describe the timin...
Gespeichert in:
Veröffentlicht in: | PloS one 2014-07, Vol.9 (7), p.e101875-e101875 |
---|---|
Hauptverfasser: | , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | e101875 |
---|---|
container_issue | 7 |
container_start_page | e101875 |
container_title | PloS one |
container_volume | 9 |
creator | Rachlis, Beth Cole, Donald C van Lettow, Monique Escobar, Michael Muula, Adamson S Ahmad, Farah Orbinski, James Chan, Adrienne K |
description | Identifying follow-up (FU) visit patterns, and exploring which factors influence them are likely to be useful in determining which patients on antiretroviral therapy (ART) may become Lost to Follow-Up (LTFU). Using an operation and implementation research approach, we sought 1) to describe the timing of FU visits amongst patients who have been on ART for shorter and longer periods of time; and 2) to determine the median time to late visits, and 3) to identify specific factors that may be associated with these patterns in Zomba, Malawi.
Using routinely collected programme monitoring data from Zomba District, we performed descriptive analyses on all ART visits among patients who initiated ART between Jan. 1, 2007-June 30, 2010. Based on an expected FU date, each FU visit was classified as early (≥4 day before an expected FU date), on time (3 days before an expected FU date/up to 6 days after an expected FU date), or late (≥7 days after an expected FU date). In total, 7,815 patients with 76417 FU visits were included. Ninety-two percent of patients had ≥2 FU visits. At the majority of visits, patients were either on time or late. The median time to a first late visit among those with 2 or more visits was 216 days (IQR: 128-359). Various patient- and visit-level factors differed significantly across Early, On Time, and Late visit groups including ART adherence and frequency of, and type of side effects.
The majority of patients do not demonstrate consistent FU visit patterns. Individuals were generally on ART for at least 6 months before experiencing their first late visit. Our findings have implications for the development of effective interventions that meet patient needs when they present early and can reduce patient losses to follow-up when they are late. In particular, time-varying visit characteristics need further research. |
doi_str_mv | 10.1371/journal.pone.0101875 |
format | Article |
fullrecord | <record><control><sourceid>gale_plos_</sourceid><recordid>TN_cdi_plos_journals_1545822108</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A418424853</galeid><doaj_id>oai_doaj_org_article_778c14650e8c437386f8787ab068a75d</doaj_id><sourcerecordid>A418424853</sourcerecordid><originalsourceid>FETCH-LOGICAL-c593t-87195ab633e32c99b09fdb768807a5459c2a918979149188ab2cc6a40aa28a943</originalsourceid><addsrcrecordid>eNptUl1rFDEUHUSxtfoPRAd8qeCs-ZwkL8JSrBYqimz74Eu4k8lss8xMxmS2pf_eTHdaulLykHBzzrn3Hk6WvcVoganAnzd-G3poF4Pv7QJhhKXgz7JDrCgpSoLo80fvg-xVjBuEOJVl-TI7IBxRSiQ_zC5Pfdv6m-JiyC9ddGP-C8bRhj7mrs-hz5f96IIdg792Adp8dWUDDLf58fL36mM-BL8O0HV2Av_xXQWf8h_Qwo17nb1ooI32zXwfZRenX1cn34vzn9_OTpbnheGKjoUUWHGoSkotJUapCqmmrkQpJRLAGVeGgMJSCYVZuiVUxJgSGAIgEhSjR9n7ne7Q-qhnS6LGiSsJwUgmxNkOUXvY6CG4DsKt9uD0XcGHtYYwOtNaLYQ0mJUcWWkYFcmrRgopoEKlBMHrpPVl7ratOlsb24_JlD3R_Z_eXem1v9YMI8LENMzxLBD8362No-5cNLZtobd-ezd3SbDClCboh_-gT283o9aQFnB941NfM4nqJcOSESb5pLV4ApVObTtnUn4al-p7BLYjmOBjDLZ52BEjPaXvfhg9pU_P6Uu0d4_9eSDdx43-A03i0-g</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1545822108</pqid></control><display><type>article</type><title>Follow-Up Visit Patterns in an Antiretroviral Therapy (ART) programme in Zomba, Malawi</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Public Library of Science (PLoS) Journals Open Access</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Free Full-Text Journals in Chemistry</source><creator>Rachlis, Beth ; Cole, Donald C ; van Lettow, Monique ; Escobar, Michael ; Muula, Adamson S ; Ahmad, Farah ; Orbinski, James ; Chan, Adrienne K</creator><contributor>Myer, Landon</contributor><creatorcontrib>Rachlis, Beth ; Cole, Donald C ; van Lettow, Monique ; Escobar, Michael ; Muula, Adamson S ; Ahmad, Farah ; Orbinski, James ; Chan, Adrienne K ; Myer, Landon</creatorcontrib><description>Identifying follow-up (FU) visit patterns, and exploring which factors influence them are likely to be useful in determining which patients on antiretroviral therapy (ART) may become Lost to Follow-Up (LTFU). Using an operation and implementation research approach, we sought 1) to describe the timing of FU visits amongst patients who have been on ART for shorter and longer periods of time; and 2) to determine the median time to late visits, and 3) to identify specific factors that may be associated with these patterns in Zomba, Malawi.
Using routinely collected programme monitoring data from Zomba District, we performed descriptive analyses on all ART visits among patients who initiated ART between Jan. 1, 2007-June 30, 2010. Based on an expected FU date, each FU visit was classified as early (≥4 day before an expected FU date), on time (3 days before an expected FU date/up to 6 days after an expected FU date), or late (≥7 days after an expected FU date). In total, 7,815 patients with 76417 FU visits were included. Ninety-two percent of patients had ≥2 FU visits. At the majority of visits, patients were either on time or late. The median time to a first late visit among those with 2 or more visits was 216 days (IQR: 128-359). Various patient- and visit-level factors differed significantly across Early, On Time, and Late visit groups including ART adherence and frequency of, and type of side effects.
The majority of patients do not demonstrate consistent FU visit patterns. Individuals were generally on ART for at least 6 months before experiencing their first late visit. Our findings have implications for the development of effective interventions that meet patient needs when they present early and can reduce patient losses to follow-up when they are late. In particular, time-varying visit characteristics need further research.</description><identifier>ISSN: 1932-6203</identifier><identifier>EISSN: 1932-6203</identifier><identifier>DOI: 10.1371/journal.pone.0101875</identifier><identifier>PMID: 25033285</identifier><language>eng</language><publisher>United States: Public Library of Science</publisher><subject>Acquired immune deficiency syndrome ; Acquired Immunodeficiency Syndrome - drug therapy ; Adolescent ; Adult ; Aged ; Aged, 80 and over ; AIDS ; Ambulatory Care ; Analysis ; Anti-HIV Agents - therapeutic use ; Antiretroviral agents ; Antiretroviral drugs ; Antiretroviral therapy ; Antiretroviral Therapy, Highly Active ; Biology and Life Sciences ; Clinical outcomes ; Developing countries ; Drug therapy ; Female ; Health Services Needs and Demand ; Highly active antiretroviral therapy ; HIV ; Human immunodeficiency virus ; Humans ; LDCs ; Malawi ; Male ; Medical personnel ; Medicine and health sciences ; Middle Aged ; Mortality ; Patient Compliance ; Patient Dropouts ; Patients ; Physical Sciences ; Population ; Public health ; Research and Analysis Methods ; Retention ; Side effects ; Systematic review ; Therapy ; Young Adult</subject><ispartof>PloS one, 2014-07, Vol.9 (7), p.e101875-e101875</ispartof><rights>COPYRIGHT 2014 Public Library of Science</rights><rights>2014 Rachlis et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2014 Rachlis et al 2014 Rachlis et al</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c593t-87195ab633e32c99b09fdb768807a5459c2a918979149188ab2cc6a40aa28a943</citedby><cites>FETCH-LOGICAL-c593t-87195ab633e32c99b09fdb768807a5459c2a918979149188ab2cc6a40aa28a943</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4102478/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4102478/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,724,777,781,861,882,2096,2915,23847,27905,27906,53772,53774,79349,79350</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25033285$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Myer, Landon</contributor><creatorcontrib>Rachlis, Beth</creatorcontrib><creatorcontrib>Cole, Donald C</creatorcontrib><creatorcontrib>van Lettow, Monique</creatorcontrib><creatorcontrib>Escobar, Michael</creatorcontrib><creatorcontrib>Muula, Adamson S</creatorcontrib><creatorcontrib>Ahmad, Farah</creatorcontrib><creatorcontrib>Orbinski, James</creatorcontrib><creatorcontrib>Chan, Adrienne K</creatorcontrib><title>Follow-Up Visit Patterns in an Antiretroviral Therapy (ART) programme in Zomba, Malawi</title><title>PloS one</title><addtitle>PLoS One</addtitle><description>Identifying follow-up (FU) visit patterns, and exploring which factors influence them are likely to be useful in determining which patients on antiretroviral therapy (ART) may become Lost to Follow-Up (LTFU). Using an operation and implementation research approach, we sought 1) to describe the timing of FU visits amongst patients who have been on ART for shorter and longer periods of time; and 2) to determine the median time to late visits, and 3) to identify specific factors that may be associated with these patterns in Zomba, Malawi.
Using routinely collected programme monitoring data from Zomba District, we performed descriptive analyses on all ART visits among patients who initiated ART between Jan. 1, 2007-June 30, 2010. Based on an expected FU date, each FU visit was classified as early (≥4 day before an expected FU date), on time (3 days before an expected FU date/up to 6 days after an expected FU date), or late (≥7 days after an expected FU date). In total, 7,815 patients with 76417 FU visits were included. Ninety-two percent of patients had ≥2 FU visits. At the majority of visits, patients were either on time or late. The median time to a first late visit among those with 2 or more visits was 216 days (IQR: 128-359). Various patient- and visit-level factors differed significantly across Early, On Time, and Late visit groups including ART adherence and frequency of, and type of side effects.
The majority of patients do not demonstrate consistent FU visit patterns. Individuals were generally on ART for at least 6 months before experiencing their first late visit. Our findings have implications for the development of effective interventions that meet patient needs when they present early and can reduce patient losses to follow-up when they are late. In particular, time-varying visit characteristics need further research.</description><subject>Acquired immune deficiency syndrome</subject><subject>Acquired Immunodeficiency Syndrome - drug therapy</subject><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>AIDS</subject><subject>Ambulatory Care</subject><subject>Analysis</subject><subject>Anti-HIV Agents - therapeutic use</subject><subject>Antiretroviral agents</subject><subject>Antiretroviral drugs</subject><subject>Antiretroviral therapy</subject><subject>Antiretroviral Therapy, Highly Active</subject><subject>Biology and Life Sciences</subject><subject>Clinical outcomes</subject><subject>Developing countries</subject><subject>Drug therapy</subject><subject>Female</subject><subject>Health Services Needs and Demand</subject><subject>Highly active antiretroviral therapy</subject><subject>HIV</subject><subject>Human immunodeficiency virus</subject><subject>Humans</subject><subject>LDCs</subject><subject>Malawi</subject><subject>Male</subject><subject>Medical personnel</subject><subject>Medicine and health sciences</subject><subject>Middle Aged</subject><subject>Mortality</subject><subject>Patient Compliance</subject><subject>Patient Dropouts</subject><subject>Patients</subject><subject>Physical Sciences</subject><subject>Population</subject><subject>Public health</subject><subject>Research and Analysis Methods</subject><subject>Retention</subject><subject>Side effects</subject><subject>Systematic review</subject><subject>Therapy</subject><subject>Young Adult</subject><issn>1932-6203</issn><issn>1932-6203</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>DOA</sourceid><recordid>eNptUl1rFDEUHUSxtfoPRAd8qeCs-ZwkL8JSrBYqimz74Eu4k8lss8xMxmS2pf_eTHdaulLykHBzzrn3Hk6WvcVoganAnzd-G3poF4Pv7QJhhKXgz7JDrCgpSoLo80fvg-xVjBuEOJVl-TI7IBxRSiQ_zC5Pfdv6m-JiyC9ddGP-C8bRhj7mrs-hz5f96IIdg792Adp8dWUDDLf58fL36mM-BL8O0HV2Av_xXQWf8h_Qwo17nb1ooI32zXwfZRenX1cn34vzn9_OTpbnheGKjoUUWHGoSkotJUapCqmmrkQpJRLAGVeGgMJSCYVZuiVUxJgSGAIgEhSjR9n7ne7Q-qhnS6LGiSsJwUgmxNkOUXvY6CG4DsKt9uD0XcGHtYYwOtNaLYQ0mJUcWWkYFcmrRgopoEKlBMHrpPVl7ratOlsb24_JlD3R_Z_eXem1v9YMI8LENMzxLBD8362No-5cNLZtobd-ezd3SbDClCboh_-gT283o9aQFnB941NfM4nqJcOSESb5pLV4ApVObTtnUn4al-p7BLYjmOBjDLZ52BEjPaXvfhg9pU_P6Uu0d4_9eSDdx43-A03i0-g</recordid><startdate>20140717</startdate><enddate>20140717</enddate><creator>Rachlis, Beth</creator><creator>Cole, Donald C</creator><creator>van Lettow, Monique</creator><creator>Escobar, Michael</creator><creator>Muula, Adamson S</creator><creator>Ahmad, Farah</creator><creator>Orbinski, James</creator><creator>Chan, Adrienne K</creator><general>Public Library of Science</general><general>Public Library of Science (PLoS)</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QG</scope><scope>7QL</scope><scope>7QO</scope><scope>7RV</scope><scope>7SN</scope><scope>7SS</scope><scope>7T5</scope><scope>7TG</scope><scope>7TM</scope><scope>7U9</scope><scope>7X2</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABJCF</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>D1I</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB.</scope><scope>KB0</scope><scope>KL.</scope><scope>L6V</scope><scope>LK8</scope><scope>M0K</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>M7S</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PATMY</scope><scope>PDBOC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PTHSS</scope><scope>PYCSY</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20140717</creationdate><title>Follow-Up Visit Patterns in an Antiretroviral Therapy (ART) programme in Zomba, Malawi</title><author>Rachlis, Beth ; Cole, Donald C ; van Lettow, Monique ; Escobar, Michael ; Muula, Adamson S ; Ahmad, Farah ; Orbinski, James ; Chan, Adrienne K</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c593t-87195ab633e32c99b09fdb768807a5459c2a918979149188ab2cc6a40aa28a943</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Acquired immune deficiency syndrome</topic><topic>Acquired Immunodeficiency Syndrome - drug therapy</topic><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>AIDS</topic><topic>Ambulatory Care</topic><topic>Analysis</topic><topic>Anti-HIV Agents - therapeutic use</topic><topic>Antiretroviral agents</topic><topic>Antiretroviral drugs</topic><topic>Antiretroviral therapy</topic><topic>Antiretroviral Therapy, Highly Active</topic><topic>Biology and Life Sciences</topic><topic>Clinical outcomes</topic><topic>Developing countries</topic><topic>Drug therapy</topic><topic>Female</topic><topic>Health Services Needs and Demand</topic><topic>Highly active antiretroviral therapy</topic><topic>HIV</topic><topic>Human immunodeficiency virus</topic><topic>Humans</topic><topic>LDCs</topic><topic>Malawi</topic><topic>Male</topic><topic>Medical personnel</topic><topic>Medicine and health sciences</topic><topic>Middle Aged</topic><topic>Mortality</topic><topic>Patient Compliance</topic><topic>Patient Dropouts</topic><topic>Patients</topic><topic>Physical Sciences</topic><topic>Population</topic><topic>Public health</topic><topic>Research and Analysis Methods</topic><topic>Retention</topic><topic>Side effects</topic><topic>Systematic review</topic><topic>Therapy</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Rachlis, Beth</creatorcontrib><creatorcontrib>Cole, Donald C</creatorcontrib><creatorcontrib>van Lettow, Monique</creatorcontrib><creatorcontrib>Escobar, Michael</creatorcontrib><creatorcontrib>Muula, Adamson S</creatorcontrib><creatorcontrib>Ahmad, Farah</creatorcontrib><creatorcontrib>Orbinski, James</creatorcontrib><creatorcontrib>Chan, Adrienne K</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Proquest Nursing & Allied Health Source</collection><collection>Ecology Abstracts</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Meteorological & Geoastrophysical Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Agricultural Science Collection</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Materials Science & Engineering Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies & Aerospace Collection</collection><collection>Agricultural & Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Materials Science Collection</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Materials Science Database</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Meteorological & Geoastrophysical Abstracts - Academic</collection><collection>ProQuest Engineering Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Agricultural Science Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Engineering Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Environmental Science Database</collection><collection>Materials Science Collection</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Engineering Collection</collection><collection>Environmental Science Collection</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>PloS one</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Rachlis, Beth</au><au>Cole, Donald C</au><au>van Lettow, Monique</au><au>Escobar, Michael</au><au>Muula, Adamson S</au><au>Ahmad, Farah</au><au>Orbinski, James</au><au>Chan, Adrienne K</au><au>Myer, Landon</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Follow-Up Visit Patterns in an Antiretroviral Therapy (ART) programme in Zomba, Malawi</atitle><jtitle>PloS one</jtitle><addtitle>PLoS One</addtitle><date>2014-07-17</date><risdate>2014</risdate><volume>9</volume><issue>7</issue><spage>e101875</spage><epage>e101875</epage><pages>e101875-e101875</pages><issn>1932-6203</issn><eissn>1932-6203</eissn><abstract>Identifying follow-up (FU) visit patterns, and exploring which factors influence them are likely to be useful in determining which patients on antiretroviral therapy (ART) may become Lost to Follow-Up (LTFU). Using an operation and implementation research approach, we sought 1) to describe the timing of FU visits amongst patients who have been on ART for shorter and longer periods of time; and 2) to determine the median time to late visits, and 3) to identify specific factors that may be associated with these patterns in Zomba, Malawi.
Using routinely collected programme monitoring data from Zomba District, we performed descriptive analyses on all ART visits among patients who initiated ART between Jan. 1, 2007-June 30, 2010. Based on an expected FU date, each FU visit was classified as early (≥4 day before an expected FU date), on time (3 days before an expected FU date/up to 6 days after an expected FU date), or late (≥7 days after an expected FU date). In total, 7,815 patients with 76417 FU visits were included. Ninety-two percent of patients had ≥2 FU visits. At the majority of visits, patients were either on time or late. The median time to a first late visit among those with 2 or more visits was 216 days (IQR: 128-359). Various patient- and visit-level factors differed significantly across Early, On Time, and Late visit groups including ART adherence and frequency of, and type of side effects.
The majority of patients do not demonstrate consistent FU visit patterns. Individuals were generally on ART for at least 6 months before experiencing their first late visit. Our findings have implications for the development of effective interventions that meet patient needs when they present early and can reduce patient losses to follow-up when they are late. In particular, time-varying visit characteristics need further research.</abstract><cop>United States</cop><pub>Public Library of Science</pub><pmid>25033285</pmid><doi>10.1371/journal.pone.0101875</doi><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1932-6203 |
ispartof | PloS one, 2014-07, Vol.9 (7), p.e101875-e101875 |
issn | 1932-6203 1932-6203 |
language | eng |
recordid | cdi_plos_journals_1545822108 |
source | MEDLINE; DOAJ Directory of Open Access Journals; Public Library of Science (PLoS) Journals Open Access; EZB-FREE-00999 freely available EZB journals; PubMed Central; Free Full-Text Journals in Chemistry |
subjects | Acquired immune deficiency syndrome Acquired Immunodeficiency Syndrome - drug therapy Adolescent Adult Aged Aged, 80 and over AIDS Ambulatory Care Analysis Anti-HIV Agents - therapeutic use Antiretroviral agents Antiretroviral drugs Antiretroviral therapy Antiretroviral Therapy, Highly Active Biology and Life Sciences Clinical outcomes Developing countries Drug therapy Female Health Services Needs and Demand Highly active antiretroviral therapy HIV Human immunodeficiency virus Humans LDCs Malawi Male Medical personnel Medicine and health sciences Middle Aged Mortality Patient Compliance Patient Dropouts Patients Physical Sciences Population Public health Research and Analysis Methods Retention Side effects Systematic review Therapy Young Adult |
title | Follow-Up Visit Patterns in an Antiretroviral Therapy (ART) programme in Zomba, Malawi |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-17T22%3A16%3A35IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_plos_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Follow-Up%20Visit%20Patterns%20in%20an%20Antiretroviral%20Therapy%20(ART)%20programme%20in%20Zomba,%20Malawi&rft.jtitle=PloS%20one&rft.au=Rachlis,%20Beth&rft.date=2014-07-17&rft.volume=9&rft.issue=7&rft.spage=e101875&rft.epage=e101875&rft.pages=e101875-e101875&rft.issn=1932-6203&rft.eissn=1932-6203&rft_id=info:doi/10.1371/journal.pone.0101875&rft_dat=%3Cgale_plos_%3EA418424853%3C/gale_plos_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1545822108&rft_id=info:pmid/25033285&rft_galeid=A418424853&rft_doaj_id=oai_doaj_org_article_778c14650e8c437386f8787ab068a75d&rfr_iscdi=true |